Loading
A phase 1/2 trial of YL201, Toripalimab, Cisplatin in nasopharyngeal carcinoma, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. is a phase 1/2 interventional study registered as NCT07258979 by MediLink Therapeutics (Suzhou) Co., Ltd., with 202 participants planned, started 2025-11-05 and due to reach its primary completion in 2028-02. Interventions recorded: YL201, Toripalimab, Cisplatin. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Shares YL201, MediLink Therapeutics, Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares Toripalimab, Platinum agents, Cisplatin, Cytotoxic chemotherapy.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics, Immune checkpoint inhibitors.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Nasopharyngeal carcinoma, Cisplatin, Cytotoxic chemotherapy.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Cisplatin, Immune checkpoint inhibitors.